A phase II study of buparlisib in relapsed or refractory thymomas.

Saved in:

Bibliographic Details
Title:	A phase II study of buparlisib in relapsed or refractory thymomas.
Authors:	Abu Zaid MI; Department of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States., Radovich M; Caris Life Science, Dallas, TX, United States., Althouse S; Department of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States., Liu H; Department of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States., Spittler AJ; Department of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States., Solzak J; Caris Life Science, Dallas, TX, United States., Badve S; Department of Biostatistics, Emory University, Atlanta, GA, United States., Loehrer PJ Sr; Department of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States.
Source:	Frontiers in oncology [Front Oncol] 2022 Oct 18; Vol. 12, pp. 891383. Date of Electronic Publication: 2022 Oct 18 (Print Publication: 2022).
Publication Type:	Journal Article
Journal Info:	Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	2234-943X
DOI:	10.3389/fonc.2022.891383